An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome

Pediatric Nephrology

Volumn 29, Issue 10, 2014, Pages 1967-1978

  Johnson, Sally ^a   Stojanovic, Jelena ^a   Ariceta, Gema ^b   Bitzan, Martin ^c   Besbas, Nesrin ^d   Frieling, Michelle ^e   Karpman, Diana ^f   Landau, Daniel ^g   Langman, Craig ^h,i   Licht, Christoph ^e   Pecoraro, Carmine ^j   Riedl, Magdalena ^k   Siomou, Ekaterini ^l   van de Kar, Nicole ^m   Walle, Johan Vande ⁿ   Loirat, Chantal ^o   Taylor, C Mark ^p  

^a Infectious Diseases Allergy   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c MONTREAL CHILDREN S HOSPITAL   (Canada)

^d HACETTEPE UNIVERSITY   (Turkey)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f LUND UNIVERSITY   (Sweden)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ CHILDREN'S MEMORIAL HOSPITAL   (United States)

^j SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^k INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^l UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ GHENT UNIVERSITY HOSPITAL   (Belgium)

^o HÔPITAL ROBERT DEBRÉ   (France)

^p BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

more..

Author keywords

Alternative complement pathway; Atypical hemolytic uremic syndrome; Chronic kidney disease; Complement dysregulation; Plasmapheresis; Thrombotic microangiopathy

Indexed keywords

ADOLESCENT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; FEMALE; HUMAN; INFANT; MALE; MEDICAL AUDIT; NEWBORN; PRACTICE GUIDELINE; PRESCHOOL CHILD; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CHILD; CHILD, PRESCHOOL; CLINICAL AUDIT; FEMALE; GUIDELINE ADHERENCE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES;

EID: 84930238594     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-014-2817-4     Document Type: Article

References (28)

1. Kavanagh D, Goodship TH (2010) Atypical hemolytic uremic syndrome. Curr Opin Hematol 17:432–438
2. Loirat C, Fremeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60
3. Le Quintrec M, Roumenina L, Noris M, Fremeaux-Bacchi V (2010) Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 36:641–652
4. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8:554–562
5. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nurnberg G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, Collard L, Majid MA, Simkova E, Nurnberg P, Rioux-Leclerc N, Moeckel GW, Gubler MC, Hwa J, Loirat C, Lifton RP (2013) Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45:531–536
6. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van der Kar N, Vandewalle J, Zimmerhackl LB, European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687–696
7. Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andre JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fremeaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180–2187
8. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C, French Society of Pediatric N (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392–2400
9. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of R, Familial HT (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279
10. Witt V, Stegmayr B, Ptak J, Wikstrom B, Berlin G, Axelsson CG, Griskevicius A, Centoni PE, Liumbruno GM, Molfettini P, Audzijoniene J, Mokvist K, Sojka BN, Norda R, Ramlow W, Blaha M, Evergren M, Tomaz J (2008) World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry. Transfus Apher Sci 39:255–260
11. Mokrzycki MH, Balogun RA (2011) Therapeutic apheresis: a review of complications and recommendations for prevention and management. J Clin Apher 26:243–248
12. Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. New Engl J Med 360:544–546
13. Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P (2011) Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 26:621–624
14. Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M (2012) Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 59:707–710
15. Dorresteijn EM, van de Kar NC, Cransberg K (2012) Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol 27:1193–1195
16. Giordano M, Castellano G, Messina G, Divella C, Bellantuono R, Puteo F, Colella V, Depalo T, Gesualdo L (2012) Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics 130:e1385–1388
17. Povey H, Vundru R, Junglee N, Jibani M (2013) Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol. doi:10.5414/CN107958
18. Vilalta R, Lara E, Madrid A, Chocron S, Munoz M, Casquero A, Nieto J (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27:2323–2326
19. Gulleroglu K, Fidan K, Hancer VS, Bayrakci U, Baskin E, Soylemezoglu O (2013) Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 28:827–830
20. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New Engl J Med 368:2169–2181
21. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. New Engl J Med 361:345–357
22. Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouviere C, Berard E, Salomon R, Fremeaux-Bacchi V, Niaudet P, Boyer O (2014) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 29:75–83
23. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M, European Working Party on Complement Genetics in Renal D (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24:475–486
24. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB, European Paediatric Research Group for HUS (2006) A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 70:423–431
25. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859
26. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Wurzner R, Jungraithmayr T, German-Austrian HUSSG (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407–415
27. Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-Durey MA, Marchbank KJ (2013) Standardisation of the factor H autoantibody assay. Immunobiology 219:9–16
28. Coats MT, Murphy T, Paton JC, Gray B, Briles DE (2011) Exposure of Thomsen-Friedenreich antigen in Streptococcus pneumoniae infection is dependent on pneumococcal neuraminidase A. Microb Pathog 50:343–349